Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children

View ORCID ProfileTrisha Patel, Michael Kelleman, Zachary West, Andrew Peter, Matthew Dove, Arene Butto, Matthew E. Oster
doi: https://doi.org/10.1101/2021.10.05.21264581
Trisha Patel
1Emory University School of Medicine, Atlanta, GA
2Children’s Healthcare of Atlanta, Atlanta, GA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Trisha Patel
Michael Kelleman
1Emory University School of Medicine, Atlanta, GA
MSPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary West
1Emory University School of Medicine, Atlanta, GA
2Children’s Healthcare of Atlanta, Atlanta, GA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Peter
1Emory University School of Medicine, Atlanta, GA
2Children’s Healthcare of Atlanta, Atlanta, GA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Dove
1Emory University School of Medicine, Atlanta, GA
2Children’s Healthcare of Atlanta, Atlanta, GA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arene Butto
1Emory University School of Medicine, Atlanta, GA
2Children’s Healthcare of Atlanta, Atlanta, GA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew E. Oster
1Emory University School of Medicine, Atlanta, GA
2Children’s Healthcare of Atlanta, Atlanta, GA
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: osterm@kidsheart.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Although rare, myocarditis in the pediatric population is a disease process that carries significant morbidity and mortality. Prior to the SARS-CoV-2 related (COVID-19) pandemic, enteroviruses were the most common cause of classic myocarditis. However, since 2020, myocarditis linked to multisystem inflammatory syndrome in children (MIS-C) is now common. In recent months, myocarditis related to COVID-19 vaccines has also been described. This study aims to compare these three different types of myocarditis with regards to clinical presentation, course, and outcomes.

Methods In this retrospective cohort study, we included all patients <21 years of age hospitalized at our institution with classic viral myocarditis from 2015-2019, MIS-C myocarditis from 3/2020-2/2021 and COVID-19 vaccine-related myocarditis from 5/2021-6/2021. We compared demographics, initial symptomatology, treatment, laboratory data, and echocardiogram findings.

Results Of 201 total participants, 43 patients had classic myocarditis, 149 had MIS-C myocarditis, and 9 had COVID-19 vaccine-related myocarditis. Peak troponin was highest in the classic myocarditis group, whereas the MIS-C myocarditis group had the highest recorded brain natriuretic peptide (BNP). There were significant differences in time to recovery of normal left ventricular ejection fraction (LVEF) for the three groups: nearly all patients with MIS-C myocarditis (n=139, 93%) and all patients with COVID-19 vaccine-related myocarditis (n=9, 100%) had normal LVEF at the time of discharge, but a lower proportion of the classic myocarditis group (n=30, 70%) had a normal LVEF at discharge (p<0.001). Three months post-discharge, 18 of 40 children (45%) in the classic myocarditis group still required heart failure treatment, whereas only one of the MIS-C myocarditis patients and none of the COVID-19 vaccine-associated myocarditis patients did.

Conclusions Compared to those with classic myocarditis, those with MIS-C myocarditis had more significant hematologic derangements and worse inflammation at presentation, but had better clinical outcomes, including rapid recovery of cardiac function. Patients with COVID-19 vaccine-related myocarditis had similar clinical presentation to patients with classic myocarditis, but their pattern of recovery was similar to those with MIS-C, with prompt resolution of symptoms and improvement of cardiac function. Long-term follow-up should focus on cardiac and non-cardiac consequences of myocarditis associated with COVID-19 illness and vaccination.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Institutional Review Board of CHOA.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclosures: The authors do not have any relationships relevant to the content of this paper to disclose. All authors have approved the final version of the article.

  • Funding Support: No funding source

Data Availability

All data referred to in the manuscript is available in our institution's electronic medical record. There is no external data set or supplemental material online that was used.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children
Trisha Patel, Michael Kelleman, Zachary West, Andrew Peter, Matthew Dove, Arene Butto, Matthew E. Oster
medRxiv 2021.10.05.21264581; doi: https://doi.org/10.1101/2021.10.05.21264581
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children
Trisha Patel, Michael Kelleman, Zachary West, Andrew Peter, Matthew Dove, Arene Butto, Matthew E. Oster
medRxiv 2021.10.05.21264581; doi: https://doi.org/10.1101/2021.10.05.21264581

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (685)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (323)
  • Neurology (2786)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)